NCT00210678

Brief Summary

The purpose of the study is to characterize intravaginal ejaculatory latency time (time between the start of vaginal intercourse and the start of intravaginal ejaculation) in men with and without premature ejaculation (PE) and to assess the validity of patient-reported outcomes.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,115

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2005

Shorter than P25 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2005

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2005

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2005

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

September 13, 2005

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 21, 2005

Completed
Last Updated

October 10, 2012

Status Verified

October 1, 2012

Enrollment Period

6 months

First QC Date

September 13, 2005

Last Update Submit

October 9, 2012

Conditions

Keywords

Erectile DysfunctionDapoxetinePremature ejaculationEjaculationSexual dysfunctionOrgasmic disorder

Outcome Measures

Primary Outcomes (2)

  • Change in Intravaginal Ejaculatory Latency Time (IELT)

    Estimated distribution of the average IELT for both the premature ejaculation (PE) and non-PE populations will be calculated.

    Day 1 to Week 8

  • Change in Patient-Reported Outcomes (PRO)

    Additional evidence of reliability and validity of PROs for patients with and without PE and their partners will be expolred. The PROs will include different parameters related to (control over ejaculation, satisfaction with sexual intercourse, personal distress, and interpersonal difficulty).

    Week 4 and Week 8

Secondary Outcomes (3)

  • Association between intravaginal ejaculatory latency time (IELT) and patient reportedout comes (PROs)

    Up to Week 8

  • Utility of the Male Sexual Function Scale and Ejaculation Questionnaires

    Day 1

  • PROs and IELT as indicators to clasify PE status.

    Up to Week 8

Study Arms (2)

Group: 1

Men with premature ejaculation (PE)

Behavioral: No intervention

Group: 2

Men without PE

Behavioral: No intervention

Interventions

No interventionBEHAVIORAL

No treatment is given to the patients as this is an observational study.

Group: 1Group: 2

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

One thousand patients (at least 200 men with premature ejaculation (PE) and at least 800 men without PE) will be enrolled in the study.

You may qualify if:

  • Must be in a stable, monogamous, sexual relationship with the same woman (18 years of age or older) for at least 6 months, who plan to maintain their relationship for the duration of the study
  • Must be in good general health
  • Patient and partner willing to avoid situations or activities that may have an effect on their sexual activity (eg, refrain from any preplanned surgery)

You may not qualify if:

  • Has history of drug abuse within the past 2 years
  • Has history of or current major psychiatric disorder such as mood disorders, anxiety disorders, schizophrenia, other psychotic disorders, or alcoholism
  • Must have erectile dysfunction
  • Patient who has decreased interest in sexual intercourse or has other forms of sexual dysfunction
  • Patient whose partner has decreased interest in sexual intercourse, painful intercourse, or other forms of female sexual dysfunction
  • Patient whose partner is more than 3 months pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Erectile DysfunctionPremature EjaculationSexual Dysfunction, PhysiologicalSexual Dysfunctions, Psychological

Condition Hierarchy (Ancestors)

Genital Diseases, MaleGenital DiseasesUrogenital DiseasesMale Urogenital DiseasesMental DisordersEjaculatory Dysfunction

Study Officials

  • Johnson & Johnson Pharmaceutical Research & Development, LLC Clinical Trial

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 21, 2005

Study Start

March 1, 2005

Primary Completion

September 1, 2005

Study Completion

September 1, 2005

Last Updated

October 10, 2012

Record last verified: 2012-10